17,261 trials
Major Depressive Disorder With Anxious Distress
Primary: Change From Baseline in Hamilton Depression Rating Scale-17 (HDRS-17) Total Score at Week 6 — -8.8; -9.4 Units on a scale — p=0.2494
Hypertension · Diabetes · Cardiovascular Disease
Primary: Change in Cardiac Global Longitudinal Strain — -1.4; -1.74; -1.14 % systolic deformation
Breast Neoplasms
Primary: Progression Free Survival (PFS) — 12.7; 11.0 Months — p=0.6534
Anemia · Dialysis-dependent Chronic Kidney Disease
Primary: Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) — 10.223; 10.059; 10.165; 9.778 grams per deciliter (g/dL)
Melanoma
Primary: Objective Response Rate of CC-122 in Combination With Nivolumab — .545; 0 proportion of participants
Gastroenteropancreatic Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 0.045 proportion of participants
Melanoma (Skin)
Primary: Tumor Response as Measured by RECIST Criteria — 6; 7 Participants
Ebola Virus Disease
Primary: Percentage of Participants With Ebola Virus Glycoprotein (GP-EBOV) Antibody Response — 40.9; 75.7; 81.1; 2.7 percentage of participants — p=<.001
Parkinson Disease
Primary: Sleep and Fatigue — 15.6; 9.0; 10.9; 6.6 units on a scale
Actinic Keratosis · Sun Damaged Skin · Solar Keratosis
Primary: Complete Clearance (%) of Actinic Keratoses (AKs) — 81; 60 percentage (%) of AK clearance
Hereditary Angioedema
Primary: Time-normalized Number of HAE Attacks (Per Month) From Week 1 to Week 17 — 2.21; 0.23; 1.52 HAE attacks per month — p=0.001
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood B-Lymphoblastic Lymphoma
Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035
Edematous Fibrosclerotic Panniculopathy · Cellulite · Laxity; Skin
Primary: Percentage of 1-Level Responders (+1 or Better Score) on the Investigator-Global Aesthetic Improvement Scale (I-GAIS) for Either Buttock or Either Thigh — 85.7; 87.5…
Sepsis · Septic Shock
Primary: Mortality Rates — 12; 7 Participants — p=0.344
Triple Negative Breast Cancer · TNBC - Triple-Negative Breast Cancer
Primary: Overall Response Rate (ORR) — 22.2; 10.0; 10.5; 53.8 percentage of participants — p=0.2252